RankingsPricing
  1. JP-listed companies
  2. Oncolys BioPharma Inc.
  3. Financials
  4. Cash and cash equivalents

Oncolys BioPharma Inc.【JP:4588】

Market cap
¥37.9B
P/E ratio
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Dec 31, 20242,411+57.29%
Dec 31, 20231,533-10.43%
Dec 31, 20221,711-50.47%
Dec 31, 20213,455+67.06%
Dec 31, 20202,068-38.13%
Dec 31, 20193,343+35.70%
Dec 31, 20182,463-14.10%
Dec 31, 20172,868+11.84%
Dec 31, 20162,564-28.88%
Dec 31, 20153,605-23.74%
Dec 31, 20144,727

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)